Expression and phosphorylation of FOXO1 influences cell proliferation and apoptosis in the gastrointestinal stromal tumor cell line GIST-T1

Wang,Tao; Zhao,Hui; Gao,Hua; Zhu,Changming; Xu,Yao; Bai,Liping; Liu,Junbo; Yan,Feng

doi:10.3892/etm.2018.5853

Expression and phosphorylation of FOXO1 influences cell proliferation and apoptosis in the gastrointestinal stromal tumor cell line GIST-T1

Authors:
- Tao Wang
- Hui Zhao
- Hua Gao
- Changming Zhu
- Yao Xu
- Liping Bai
- Junbo Liu
- Feng Yan
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The Affiliated Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, P.R. China, Medical Cosmetology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian 361009, P.R. China
Published online on: February 8, 2018 https://doi.org/10.3892/etm.2018.5853
Pages: 3197-3202
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3‑kinase (PI3K) pathways are activated during pathogenesis of gastrointestinal stromal tumors (GISTs). Forkhead box protein O1 (FOXO1) is a transcription factor regulated by the MAPK and PI3K pathways and is associated with multiple metabolic reactions. The present study aims to investigate the association of FOXO1 with cell proliferation and apoptosis in the cell line, GIST‑T1. Cell counting kit‑8 assay revealed that cell growth was inhibited by the PI3K inhibitor, LY294002, and/or MAPK inhibitor, UO126. Western blotting demonstrated that the expression of p‑FOXO1 and B‑cell lymphoma 2 (Bcl2) were significantly reduced, whereas the expression of Bcl‑2‑associated X protein was significantly increased following treatment with LY294002 and/or UO126 (all P<0.05). However, no significant change was revealed in the level of total FOXO1. Flow cytometry revealed that apoptosis was significantly increased by the pathway inhibitors (P<0.05). Specifically, the proportion of cells in the G1 phase was increased whereas the proportion in the S phase was reduced. The changes of protein expression and cell apoptosis were more evident in the LY294002 + UO126 group than in either single‑inhibitor group. The results indicated that FOXO1 was able to affect cell proliferation, apoptosis and the cell cycle of GISTs. The regulation of FOXO1 was part of the PI3K and MAPK signaling network, while this regulation was mostly activated by phosphorylation of FOXO1.

View Figures

View References

1	Mazur MT and Clark HB: Gastric stromal tumors: Reappraisal of histogenesis. Am J Surg Pathol. 7:507–519. 1983. View Article : Google Scholar : PubMed/NCBI
2	Joensuu H, Hohenberger P and Corless CL: Gastrointestinal stromal tumour. Lancet. 382:973–983. 2013. View Article : Google Scholar : PubMed/NCBI
3	Miettinen M and Lasota J: Gastrointestinal stromal tumors. Gastroenterol Clin North Am. 42:399–415. 2013. View Article : Google Scholar : PubMed/NCBI
4	Duensing A, Heinrich MC, Fletcher CD and Fletcher JA: Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest. 22:106–116. 2004. View Article : Google Scholar : PubMed/NCBI
5	Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI
6	Sako H, Fukuda K, Saikawa Y, Nakamura R, Takahashi T, Wada N, Kawakubo H, Takeuchi H, Ohmori T and Kitagawa Y: Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells. PLoS One. 9:e1076132014. View Article : Google Scholar : PubMed/NCBI
7	Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, et al: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:295–302. 2013. View Article : Google Scholar : PubMed/NCBI
8	Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G, Yozgat Y, Manova K, Antonescu CR and Besmer P: Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA. 103:pp. 12843–12848. 2006; View Article : Google Scholar : PubMed/NCBI
9	Patel S: Exploring novel therapeutic targets in GIST: Focus on the PI3K/Akt/mTOR pathway. Curr Oncol Rep. 15:386–395. 2013. View Article : Google Scholar : PubMed/NCBI
10	Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S, Wang D, Feng J, Yu L and Zhu WG: Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol. 12:665–675. 2010. View Article : Google Scholar : PubMed/NCBI
11	Prasad SB, Yadav SS, Das M, Govardhan HB, Pandey LK, Singh S, Pradhan S and Narayan G: Down regulation of FOXO1 promotes cell proliferation in cervical cancer. J Cancer. 5:655–662. 2014. View Article : Google Scholar : PubMed/NCBI
12	Matsumoto M, Pocai A, Rossetti L, Depinho RA and Accili D: Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 6:208–216. 2007. View Article : Google Scholar : PubMed/NCBI
13	Roy SK, Srivastava RK and Shankar S: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
14	Ai J, Duan J, Lv X, Chen M, Yang Q, Sun H, Li Q, Xiao Y, Wang Y, Zhang Z, et al: Overexpression of FoxO1 causes proliferation of cultured pancreatic beta cells exposed to low nutrition. Biochemistry. 49:218–225. 2010. View Article : Google Scholar : PubMed/NCBI
15	Taguchi T, Sonobe H, Toyonaga S, Yamasaki I, Shuin T, Takano A, Araki K, Akimaru K and Yuri K: Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab Invest. 82:663–665. 2002. View Article : Google Scholar : PubMed/NCBI
16	Hsu KH, Tsai HW, Lin PW, Hsu YS, Lu PJ and Shan YS: Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors. World J Surg Oncol. 12:1892014. View Article : Google Scholar : PubMed/NCBI
17	Ríos-Moreno MJ, Jaramillo S, Díaz-Delgado M, Sánchez-León M, Trigo-Sánchez I, Padillo JP, Amérigo J and González-Cámpora R: Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors. Anticancer Res. 31:3019–3025. 2011.PubMed/NCBI
18	Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, et al: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 24:4764–4774. 2006. View Article : Google Scholar : PubMed/NCBI
19	Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, et al: AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 146:697–708. 2011. View Article : Google Scholar : PubMed/NCBI
20	Asada S, Daitoku H, Matsuzaki H, Saito T, Sudo T, Mukai H, Iwashita S, Kako K, Kishi T, Kasuya Y and Fukamizu A: Mitogen-activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1. Cell Signal. 19:519–527. 2007. View Article : Google Scholar : PubMed/NCBI
21	Qiang L, Banks AS and Accili D: Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization. J Biol Chem. 285:27396–27401. 2010. View Article : Google Scholar : PubMed/NCBI
22	Moriishi T, Kawai Y, Komori H, Rokutanda S, Eguchi Y, Tsujimoto Y, Asahina I and Komori T: Bcl2 deficiency activates FoxO through Akt inactivation and accelerates osteoblast differentiation. PLoS One. 9:e866292014. View Article : Google Scholar : PubMed/NCBI
23	Teijido O and Dejean L: Upregulation of Bcl2 inhibits apoptosis-driven BAX insertion but favors BAX relocalization in mitochondria. FEBS Lett. 584:3305–3310. 2010. View Article : Google Scholar : PubMed/NCBI
24	Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y and McIntosh CH: Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem. 280:22297–22307. 2005. View Article : Google Scholar : PubMed/NCBI
25	Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB and Brugge JS: Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 21:227–239. 2012. View Article : Google Scholar : PubMed/NCBI